Cantor Fitzgerald Reiterates Overweight on LifeMD, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on LifeMD (NASDAQ: LFMD) and maintained a $9 price target for the company's stock.
December 14, 2023 | 5:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Sarah James reaffirmed an Overweight rating on LifeMD and kept the price target at $9, indicating a positive outlook for the stock.
The reiteration of an Overweight rating by a Cantor Fitzgerald analyst suggests a bullish stance on LifeMD's stock. Maintaining a $9 price target indicates the analyst's belief that the stock has the potential to reach or exceed this value in the short term, which could positively influence investor sentiment and potentially drive the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100